Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

Trachoma is the leading cause of infectious blindness in the world, with Ethiopia the most impacted country in Africa. In a ...

John Kempen, MD, MPH, PhD, MHS , Director of Epidemiology for Ophthalmology at Mass Eye and Ear and Harvard Medical School, is the lead author of a ...

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...

While online coaching improves asthma management short-term, it does not sustain physical activity changes, highlighting the ...

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

Background The global surge in ultra-processed food (UPF) consumption is a major public health challenge, particularly among ...

New peer-reviewed research adds to substantial body of scientific evidence highlighting the safety of natural kratom leaf ...

There are no FDA-approved therapies for the treatment of OI.

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Hera Women's Health is highlighting results from the PRIME multicenter randomized controlled trial sponsored by Sera Prognostics, Inc., with Brian K. Iriye, MD (Hera Women's Health) serving as the ...